HIV generics to take over the antivirals market

HIV-generics-take-over-the-antivirals-marketGenerics are predicted to take over the antiviral drugs market, especially in the case of HIV medication, as a series of patent expiries will open opportunities for ambitious companies to seize huge revenue, according to a new report by GBI Research.

EMA recommends restricting use of trimetazidine-containing medicines

The European Medicines Agency has recommended restricting the use of trimetazidine containing medicines in the treatment of patients with angina pectoris to second-line, add-on therapy. For all other indications the Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of these medicines were not sufficiently demonstrated and did not outweigh the risks. The CHMP therefore recommended their deletion from the marketing authorisation.

Cold-chain storage critical to pharma’s future

As temperature sensitive drugs become more prevalent, pharmaceutical companies are increasing reliance, and spending, on cold-chain storage, according to a report by GBI Research.

The new report - Pharmaceutical Supply Chain in the US - Advances in RFID and ePedigree Systems to Limit Drug Counterfeits - states that pharmaceutical firms around the world are investing more and more in this storage solution in response to the increase in treatments such as vaccines, biologics, specialty pharmaceuticals and personalised medicines that must be maintained at low temperatures.

European Medicines Agency recommends first medical treatment for patients with short bowel syndrome

The European Medicines Agency has recommended approval of Revestive (teduglutide) for the treatment of adult patients with short bowel syndrome. This is the first medical treatment recommended for approval in Europe in this rare but seriously debilitating condition.

MEK inhibitors: a new weapon in the fight against melanoma

Cancer cell signalling has long been an attractive target for oncology drug development. Increased activation of cell survival signalling cascades promotes tumour cell growth and makes cancer cells difficult to kill. Inhibiting proteins that are involved in these survival pathways is one strategy to selectively destroy cancerous cells. The mitogen activated protein kinase (MAPK) pathway is one such signalling cascade that, when activated, promotes cell survival. Preclinical research has found that this pathway is activated in most melanomas; consequently, one of the key kinases involved in this pathway, MEK, has become the focus of targeted therapies for the treatment of melanoma.

Would you like to receive our FREE e-newsletter?

* indicates required